.jpg)
technology PLATFORM
Accure's TiMES technology integrates multiplex automation, electronic detection and machine learning into compact systems to accelerate biomarker/target discovery and testing. By converting molecular data from biological fluid directly into electrical signals, Accure bypasses the limitations of existing optical diagnostic devices and significantly improves the speed and sensitivity of its tests.
The technology was initially developed at the Harvard Medical School and Massachusetts General Hospital. Together with clinical and industry partners, Accure has developed unique solutions for cancer, neurodegeneration and other complex diseases.

Selected Publications
-
A Rapid Saliva Test for Monitoring Immune Protection against SARS-CoV-2 and its Variants. MedRxiv (2021)
-
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun (2015)
-
Integrated Magneto-Electrochemical Sensor for Exosome Analysis. ACS Nano (2016)
-
Integrated Magneto-Chemical Sensor For On-Site Food Allergen Detection. ACS Nano (2017)
-
Integrated Biosensor for Rapid and Point-Of-Care Sepsis Diagnosis. ACS Nano (2018)
-
Bioassay for monitoring the anti-aging effect of cord blood treatment. Theranostics (2019)